SOPHiA GENETICS (NASDAQ:SOPH) CFO Sells $12,895.20 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CFO George Cardoza sold 1,592 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $8.10, for a total value of $12,895.20. Following the completion of the transaction, the chief financial officer owned 306,726 shares in the company, valued at $2,484,480.60. The trade was a 0.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

George Cardoza also recently made the following trade(s):

• On Monday, September 21st, George Cardoza sold 774 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.33, for a total value of $6,447.42.

SOPHiA GENETICS Stock Performance

Shares of SOPH opened at $7.41 on Friday. The stock has a 50 day moving average of $7.91 and a 200 day moving average of $6.16. The company has a market capitalization of $621.62 million, a price-to-earnings ratio of -6.44 and a beta of 0.95. SOPHiA GENETICS SA has a 12 month low of $3.75 and a 12 month high of $8.98. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The business had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. As a group, sell-side analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SOPH shares. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. BTIG Research boosted their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, HC Wainwright increased their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, SOPHiA GENETICS presently has an average rating of “Hold” and a consensus target price of $10.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Maven Securities LTD purchased a new stake in SOPHiA GENETICS in the 2nd quarter worth about $866,000. AWM Investment Company Inc. purchased a new stake in SOPHiA GENETICS during the second quarter valued at about $9,809,000. Sei Investments Co. purchased a new stake in SOPHiA GENETICS during the first quarter valued at about $1,772,000. Hennion & Walsh Asset Management Inc. bought a new position in SOPHiA GENETICS during the second quarter worth about $567,000. Finally, Hodges Capital Management Inc. bought a new position in SOPHiA GENETICS during the first quarter worth about $2,157,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.